Literature DB >> 27043708

Comparison of Visceral Fat Measures with Cardiometabolic Risk Factors in Healthy Adults.

Kyoungjune Pak1, Seung Hun Lee2, Jeong Gyu Lee2, Ju Won Seok3, In Joo Kim1.   

Abstract

We aimed to evaluate the associations of visceral adiposity with cardiometabolic risk factors in normal subjects with integrated 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). A total of 58 normal subjects who underwent 18F-FDG PET/CT scan for cancer screening were included in this study. Volume and average Hounsfield unit (HU) of visceral adipose tissue (VAT) was measured from CT components of integrated PET/CT. Standardized uptake values (SUVmax) of liver, spleen, lumbar spine and ascending aorta (AA) were measured from PET components of integrated PET/CT. Body mass index (coefficient 78.25, p = 0.0259), glucose (37.62, p<0.0001), insulin (348.90, p = 0.0011), logarithmic transformation of homeostatic model assessment index-insulin resistance (-2118.37, p = 0.0007), and VAT HU (-134.99, p<0.0001) were independently associated with VAT volume. Glucose (0.1187, p = 0.0098) and VAT volume (-0.004, p<0.0001) were found to be associated with VAT HU. Both VAT volume and VAT HU of whole abdominal cavity is significantly associated with cardiometabolic risk factors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27043708      PMCID: PMC4820273          DOI: 10.1371/journal.pone.0153031

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

According to the most recent estimates of the 2013 Korean national health and nutrition examination survey, 37.8% or men and 25.1% of women classified as obese[1]. The prevalence of obesity has increased over the last decade and numerous prospective cohort studies have shown that obese persons, defined by a body mass index (BMI), have an increased risk of hypertension, cardiovascular disease, and all cause mortality [1-4]. Furthermore, the distribution of fat depots, such as visceral abdominal adipose tissue (VAT), independent of overall obesity, has been associated with cardiometabolic risks [5, 6]. Several studies have shown the area of VAT, measured by single-slice computed tomography (CT) image at L4-5 intervertebral space, could reflect the amount of VAT and may be the predictor of cardiometabolic complications [7, 8]. However, using a single slice of CT image to represent total VAT may not be appropriate for all population because of there are race, sex or age differences in the distribution of VAT across the abdomen [9]. Furthermore, controversy exists which measurement site is the best correlated to not only VAT volumes but also cardiometabolic risk factors [9-11]. Thus, volumetric quantification of whole abdomen is the gold standard to assess amount of VAT [5, 12]. Previous studies suggested CT attenuation of adipose tissue, measured in Hounsfield Units (HU) as a density on x-ray imaging was adopted as a marker of fat quality and lower CT attenuation was associated with higher cardiovascular disease risk, independent of fat volume [13-15]. Although, these studies demonstrated that regional CT imaging allows the assessment of volume and density of adipose tissue, they could not assessed the whole adipose tissue of abdominal cavity. In the present study, we measured total volume and attenuation of whole VAT of abdominal cavity with integrated 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scans to evaluate the associations between cardiometabolic risks and other variables from PET/CT.

Materials and Methods

Patients

A total of 58 subjects who underwent 18F-FDG PET/CT scan for cancer screening between February 2011 and September 2014 were included in this study. Study participants with known malignancy or age<18 years were excluded (Fig 1).
Fig 1

Flow diagram of study subjects.

This study was designed as a retrospective review of participants’ charts. Participants’ information was anonymized by JG Lee. The consent from participants was not needed according to Institutional Review Board of Pusan National University Hospital (PNUH-2015-07892).

Measurement

Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). Waist circumference was measured at the narrowest point between the lower border of the rib cage and the iliac crest, at the end of a normal expiration of breath and to the nearest 0.1cm. Percentage of body fat and total fat mass was measured by bioelectric impedance analysis (Inbody 3.0, Biospace Co, Ltd, Korea). Fasting plasma glucose was measured by the glucose oxidase method using a Synchron LX20 (Beckman Coulter, Fullerton, CA, USA). Fasting insulin was measured using a radioimmunoassay (Diagnostic Product Corporation, Los Angeles, CA, USA) with antibody-coated tubes. A mercury sphygmomanometer was used for measurement of blood pressure of each subject in sitting position after a 10-min rest. Homeostatic model assessment index-insulin resistance (HOMA-IR) was calculated using the formula for estimation of insulin sensitivity: fasting insulin (IU/mL) x fasting glucose (mg/dL)/405[16]. Lipid profile was measured by an enzymatic colorimetric method using with an autoanalyzer (Hitachi 747; Hitachi Corp., Tokyo, Japan).

Integrated 18F-FDG PET/CT

Patients were injected intravenously with 5.18MBq/kg of 18F-FDG, following a fasting period of at least 6 h to achieve a blood glucose level of < 140 mg/kg. PET/CT scans commenced 60 min following injection using integrated PET/CT scanners (Gemini TF, Philips, Milpitas, CA, USA). During image acquisition, a CT scan was obtained first for attenuation correction with a slice thickness of 4mm (120kV), and an emission scan was obtained consecutively from the skull base to the proximal thigh with a field-of-view of 576mm. PET images were reconstructed using an iterative algorithm (ordered-subset expectation maximization, iteration: 3, subsets: 33) with an image matrix size of 144 x 144. Two nuclear physicians, blinded to clinical data, reviewed retrospectively PET/CT datasets.

Image analysis

18F-FDG PET/CT images were reviewed by 2 experienced nuclear physicians with pmod version 3.2 (PMOD Technologies Ltd, Zürich, Switzerland).

a. PET

Standardized uptake values (SUV) were calculated as the tissue concentration of radioactivity (kBq/mL) divided by the injected dose per weight (kBq/g). A circular region of interest with a diameter of 2cm was placed in the right lobe of the liver (Liver SUV) and center of spleen (Spleen SUV), avoiding vessels, bile ducts, calcifications, and artifacts to measure maximum SUV (SUVmax). SUVmax of each lumbar spine was measured on body of L1-5, was averaged, and defined as lumbar SUV. SUVmax of blood pool was evaluated within the wall of the ascending aorta on every 5 axial image, and the average was defined as AA SUV.

b. CT

Volume (VAT volume, ml) and average Hounsfield unit (VAT HU) of visceral adipose tissue was measured from CT components of integrated PET/CT scans. VAT was delineated as follows: 1) manually outlining VOI of the abdominal muscular wall excluding vertebral column and paraspinal muscles, 2) defining voxels between -195HU and -45HU, making a template atlas, 4) applying a template atlas to CT, and 5) measuring parameters (Fig 2).
Fig 2

Measurement of whole visceral adipose tissue.

(A) Manually outlining volume-of-interest of the abdominal muscular wall, (B) defining voxels between -195HU and -45HU, making a template atlas, and (C) applying a template atlas to CT.

Measurement of whole visceral adipose tissue.

(A) Manually outlining volume-of-interest of the abdominal muscular wall, (B) defining voxels between -195HU and -45HU, making a template atlas, and (C) applying a template atlas to CT.

Statistical analysis

All continuous variables were expressed as mean±standard deviation. Subjects were divided into 2 groups with median value of VAT volume and VAT HU, analyzed with T-test. D’Agostino-Pearson test was adopted to assess normal distribution. Multiple regression method was used to examine the relationship between VAT volume, VAT HU and other variables after adjustment with age and sex. Variables with p value <0.05 were entered into model with enter method. A p value of < 0.05 was considered statistically significant. All statistical analyses were performed using the MedCalc software package (ver. 12.6.0.0, MedCalc, Mariakerke, Belgium).

Results

Demographics are summarized in Table 1. The mean age was 48.4±8.3 years with a range between 39 and 73. Thirty-eight subjects were male, 20 were female. The mean VAT volume was 3,285ml and the mean VAT HU was -95.2.
Table 1

Demographics.

CharacteristicAllHigh VAT volumeLow VAT volumep
Age (years)48.4±8.349.2±8.147.7±8.50.4900
Sex (M/F)38/2026/312/170.0002
BMI (kg/m2)25.4±4.926.2±2.022.4±2.4<0.0001
Waist circumference (cm)84.7±7.690.4±4.478.9±5.5<0.0001
AST (IU/L)21.7±6.623.6±6.819.7±5.90.0251
ALT (IU/L)22.4±12.328.1±12.816.7±8.90.0002
Hb (g/dL)14.4±1.515.2±1.213.7±1.50.0001
Hct (%)42.5±4.044.3±3.340.7±3.90.0004
WBC (x103/uL)5.7±1.76.5±1.84.9±1.10.0001
Platelet (x103/uL)235.9±52.2234.2±62.0237.6±41.10.8077
Lipid
    Total cholesterol (mg/dL)195.4±33.4194.2±33.5196.7±33.90.7742
    LDL cholesterol (mg/dL)125.4±31.8126.8±31.6124.0±32.40.7411
    HDL cholesterol (mg/dL)51.3±14.546.0±13.856.6±13.50.0049
lnTg (mg/dL)4.8±0.54.9±0.54.7±0.40.1340
Glucose (mg/dL)91±1496.0±16.586.0±7.40.0041
Insulin (uIU/mL)5.3±2.46.2±2.94.4±1.20.0021
lnHOMA-IR0.1±0.50.3±0.5-0.1±0.30.0012
CRP (mg/dL)0.1±0.10.11±0.100.04±0.060.0016
AA SUV2.0±0.32.1±0.31.8±0.30.0006
Lumbar SUV1.6±0.31.7±0.31.5±0.20.0045
Liver SUV2.5±0.32.6±0.32.3±0.2<0.0001
Spleen SUV1.9±0.32.0±0.31.7±0.3<0.0001
VAT HU-95.2±5.6-99.1±4.0-91.4±4.2<0.0001

VAT, visceral adipose tissue; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; Hb, hemoglobin; Hct, hematocrit; WBC, white blood cell; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ln, logarithmic transformation; Tg, triglyceride; HOMA-IR, homeostatic model assessment index-insulin resistance; CRP, c-reactive protein; AA, ascending aorta; SUV, standardized uptake value; HU, hounsfield unit.

VAT, visceral adipose tissue; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; Hb, hemoglobin; Hct, hematocrit; WBC, white blood cell; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ln, logarithmic transformation; Tg, triglyceride; HOMA-IR, homeostatic model assessment index-insulin resistance; CRP, c-reactive protein; AA, ascending aorta; SUV, standardized uptake value; HU, hounsfield unit.

Comparisons between high and low VAT volume and VAT HU

Subjects were divided into 2 groups according to VAT volume and VAT HU. In high VAT volume (>3,298ml) and low VAT HU (≤-94.7) groups, both systolic and diastolic BP, BMI, waist circumference, insulin, lnHOMA-IR, CRP, AA SUV, lumbar SUV, and spleen SUV were higher. HDL cholesterol was lower in both high VAT volume (p = 0.0049) and low VAT HU (p = 0.0001) groups. Glucose (p = 0.0041), and liver SUV (p<0.0001) were higher in high VAT volume group, while LDL cholesterol (p = 0.0158) was higher in low VAT HU group.

Univariable and multivariable regression analyses of VAT volume

In univariable analysis, VAT volume showed positive associations with BMI (coefficient 317.91, p<0.0001), waist circumference (144.58, p<0.0001), glucose (46.42, p = 0.0001), insulin (233.70, p = 0.0003), lnHOMA-IR (1228.11, p = 0.0002), and PET parameters of AA SUV (2218.06, p<0.0001), lumbar SUV (2175.40, p = 0.0001), liver SUV (1701.84, p = 0.0002), and spleen SUV (1973.62, p<0.0001) and negative associations with HDL cholesterol (-37.44, p = 0.0008), and VAT HU (-204.09, p<0.0001). In multivariable analysis, BMI (78.25, p = 0.0259), glucose (37.62, p<0.0001), insulin (348.90, p = 0.0011), lnHOMA-IR (-2118.37, p = 0.0007), and VAT HU (-134.99, p<0.0001) were independently associated with VAT volume. Table 2 shows the results of multivariable regression analyses of VAT volume.
Table 2

Multivariable Regression Analyses–VAT volume (adjustment with age and sex).

Coefficienttp
BMI78.252.310.0259
LabHDL Cholesterol-10.59-1.830.0747
Glucose37.625.13<0.0001
Insulin348.903.500.0011
lnHOMA-IR-2118.37-3.630.0007
PETAA SUV-22.05-0.080.9376
Lumbar SUV517.901.860.0701
Liver SUV205.720.840.4073
Spleen SUV77.860.300.7637
CTVAT HU-134.99-7.95<0.0001

VAT, visceral adipose tissue; BMI, body mass index; HDL, high-density lipoprotein; ln, logarithmic transformation; HOMA-IR, homeostatic model assessment index-insulin resistance; AA, ascending aorta; SUV, standardized uptake value; HU, hounsfield unit.

VAT, visceral adipose tissue; BMI, body mass index; HDL, high-density lipoprotein; ln, logarithmic transformation; HOMA-IR, homeostatic model assessment index-insulin resistance; AA, ascending aorta; SUV, standardized uptake value; HU, hounsfield unit.

Univariable and multivariable regression analyses of VAT HU

VAT HU was associated positively with HDL cholesterol (0.15, p = 0.0011) and negatively with BMI (-1.12, p<0.0001), waist circumference (-0.53, p<0.0001), total cholesterol (-0.04, p = 0.0346), LDL cholesterol (-0.05, p = 0.0104), lnTg (-4.08, p = 0.0040), glucose (-0.12, p = 0.0289), insulin (-0.88, p = 0.0013), lnHOMA-IR (-4.58, p = 0.0012), VAT volume (-0.004, p<0.0001), and PET parameters of AA SUV (-8.34, p = 0.0001), lumbar SUV (-5.65, p = 0.0192), liver SUV (-5.16, p = 0.0099), and spleen SUV (-6.20, p = 0.0023). In multivariable analysis, glucose (0.1187, p = 0.0098), and VAT volume (-0.004, p<0.0001) were found to be associated with VAT HU. Table 3 shows the results of multivariable regression analysis of VAT HU.
Table 3

Multivariable Regression Analyses–VAT HU (adjustment with age and sex).

Coefficienttp
BMI0.150.680.5012
Waist circumference-0.08-0.740.4630
LabTotal cholesterol-0.10-1.620.1129
LDL cholesterol0.061.050.2996
HDL cholesterol0.060.910.3686
lnTg1.240.750.4595
Glucose0.122.710.0098
Insulin0.951.650.1059
lnHOMA-IR-6.46-1.910.0634
PETAA SUV-2.08-1.440.1580
Lumbar SUV2.401.610.1144
Liver SUV1.311.020.3144
Spleen SUV-0.42-0.300.7678
CTVAT volume-0.004-7.15<0.0001

VAT, visceral adipose tissue; HU, hounsfield unit; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ln, logarithmic transformation; Tg, triglyceride; HOMA-IR, homeostatic model assessment index-insulin resistance; AA, ascending aorta; SUV, standardized uptake value.

VAT, visceral adipose tissue; HU, hounsfield unit; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ln, logarithmic transformation; Tg, triglyceride; HOMA-IR, homeostatic model assessment index-insulin resistance; AA, ascending aorta; SUV, standardized uptake value.

Discussion

It is well established that visceral adiposity is associated with cardiometabolic risk factors [17]. In this study, both VAT HU and VAT volume were significantly associated with cardiometabolic risk factors. In addition, VAT HU showed a strong association with VAT volume negatively. These results are similar with previous studies with VAT volume (table 4)[14, 15, 18–20]. CT scans were acquired as a substudy of the Framingham Heart Study[14, 15, 18, 19]. In all 4 reports from Framinghamg Heart Study, 25 contiguous 5-mm thickness CT scan was done in participants[14, 15, 18, 19]. Both volume and HU from VAT and SAT were measured from 25 contiguous 5-mm thickness CT scans. However, 25 contiguous 5-mm thickness CT covers 125 mm of abdomen above S1 level, which is a part of VAT in a subject [13]. In the other study by Tahara et al[20], they adopted PET/CT to measure the metabolic activity of fat tissue. However, 11 contiguous 4-mm thickness CT was included in measuring parameters, covering 44 mm of abdomen, a very small part of the whole abdomen. Until now, measurement of CT-based VAT area is common in a clinical setting. As VAT is distributed in whole abdomen, measuring an area on a single slice at L1 [21], L4/5 level[22, 23] or several slices from L2 to L5 [24] may not be enough to represent VAT of abdomen. Therefore, we measured a whole VAT delineating abdominal muscular wall, which might be the most accurate way to estimate VAT.
Table 4

Previous studies of VAT volume.

AuthorYearImage acquisitionLevelVariablesParameters of fat
Rosenquist et al.[14]201325 contiguous 5-mm thickness CTabove S1VAT and SATVolume and HU
Britton et al.[18]201325 contiguous 5-mm thickness CTabove S1VAT and SATVolume
Alvey et al.[15]201425 contiguous 5-mm thickness CTabove S1VAT and SATVolume and HU
Tahara et al.[20]201511 contiguous 4-mm thickness CTumbilicusVAT and SATArea, HU, and SUV
Rosenquist et al.[19]201525 contiguous 5-mm thickness CTabove S1VAT and SATVolume and HU

VAT, visceral adipose tissue; CT, computed tomography; SAT, subcutaneous adipose tissue; HU, hounsfield unit; SUV, standardized uptake value.

VAT, visceral adipose tissue; CT, computed tomography; SAT, subcutaneous adipose tissue; HU, hounsfield unit; SUV, standardized uptake value. Interestingly, not only VAT volume, but also VAT HU were statistically associated with cardiometabolic risk factors in present study. The mechanisms are not fully clarified, however, a possible explanation is a role of adipocyte hypertrophy. Attenuation of tissue determined by CT is a marker of lipid content and decreased attenuation represents more lipid-dense fat tissue [25]. Cellular lipid contents help to determine adipocyte cell size [26]. Increased adipocyte cell size is associated with reduced number of preadipocytes which is a precursor cells able to differentiate into adipocyte [27]. Impaired adipocyte differentiation is well known to be related with cardiometabolic complications. Furthermore, increased adipocyte size is also correlated with decreased adiponectin concentrations [28]. It has been found that decreased plasma adiponectin concentrations are associated with progression of atherosclerosis and increased incidence of CVD[29]. Taken together, lower attenuation may represents adipocyte hypertrophy, which predicts more adverse cardiometabolic risk. It is certain that, increased amount of VAT is associated with adverse cardiometabolic risk [12]. Numerous studies have demonstrated that the VAT compartment is metabolically active and secreting multiple biologically active molecules such as adipokines, inflammatory markers, vasoactive substances, markers of hemostasis, and growth factors [12, 30, 31]. To assess amount of VAT, the gold standard is the volumetric CT measurement [5, 12]. Because CT is limited by amount of radiation exposure and high cost, waist circumference and BMI, the simple anthropometric markers, commonly used measurement for VAT in the clinical practice and there are data suggesting that theses indices are associated with cardiometabolic risk factors [32]. Although PET parameters of AA, lumbar spine, liver, and spleen were associated independently with neither VAT volume nor VAT HU, univariable analysis showed significant associations between PET parameters and both VAT volume and VAT HU. Recent studies reported that FDG uptake could be useful tool for the measurement of inflammation [33]. Histological studies indicated that FDG accumulation was localized within the atherosclerotic plaques [34]. Moreover, FDG uptake of aorta was significantly correlated with LDL-C concentration and atherosclerosis [35]. Tahara et al have presented that FDG uptake of VAT and SAT measured is involved in adipose tissue inflammation [20]. However, misregistration between PET and CT scans can be problematic to measure FDG activity in whole VAT and SAT. VAT and SAT show a faint FDG uptake in a normal subject with SUV less than 1 [36]. Including urine FDG activities from kidney, bladder, or ureter into VAT VOI can lead to increase in metabolic activity in VAT by the mistake. In addition, although VAT is delineated by abdominal muscular layer, SAT is not defined with upper or lower border. Therefore, measuring whole SAT can be subjective and problematic. This study has several limitations. First, this is a cross sectional study with a small sample size with a retrospective design, thereby precluding inferences of causality or temporality. Second, although FDG-PER/CT imaging was performed and FDG uptake was assessed in the ascending aorta and spleen, we were unable to assess metabolic activity of VAT and SAT because of misregistration. Third, other non-invasive methods for cardiometabolic risks, such as calcium score or carotid intima-media thickness, could not be evaluated.

Conclusion

Both VAT volume and VAT HU is significantly associated with cardiometabolic risk factors. This is the first study that measured whole abdominal cavity to estimate VAT.

Data of this study.

(ZIP) Click here for additional data file.
  35 in total

Review 1.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.

Authors:  B L Wajchenberg
Journal:  Endocr Rev       Date:  2000-12       Impact factor: 19.871

Review 2.  The role of leptin/adiponectin ratio in metabolic syndrome and diabetes.

Authors:  Patricio López-Jaramillo; Diego Gómez-Arbeláez; Jose López-López; Cristina López-López; Javier Martínez-Ortega; Andrea Gómez-Rodríguez; Stefany Triana-Cubillos
Journal:  Horm Mol Biol Clin Investig       Date:  2014-04

3.  Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT.

Authors:  Nobuhiro Tahara; Sho-Ichi Yamagishi; Norihiro Kodama; Atsuko Tahara; Akihiro Honda; Yoshikazu Nitta; Sachiyo Igata; Takanori Matsui; Masayoshi Takeuchi; Hayato Kaida; Seiji Kurata; Toshi Abe; Yoshihiro Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2015-02-19       Impact factor: 5.958

4.  Regional intra-subject variability in abdominal adiposity limits usefulness of computed tomography.

Authors:  Jerry R Greenfield; Katherine Samaras; Donald J Chisholm; Lesley V Campbell
Journal:  Obes Res       Date:  2002-04

Review 5.  18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation.

Authors:  Hongming Zhuang; Abass Alavi
Journal:  Semin Nucl Med       Date:  2002-01       Impact factor: 4.446

6.  Obesity and unhealthy life-years in adult Finns: an empirical approach.

Authors:  Tommy L S Visscher; Aila Rissanen; Jacob C Seidell; Markku Heliövaara; Paul Knekt; Antti Reunanen; Arpo Aromaa
Journal:  Arch Intern Med       Date:  2004-07-12

7.  Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease.

Authors:  Donghee Kim; Goh Eun Chung; Min-Sun Kwak; Hyo Bin Seo; Jin Hwa Kang; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Chung Yong Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-27       Impact factor: 11.382

8.  Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects.

Authors:  Y Saijo; N Kiyota; Y Kawasaki; Y Miyazaki; J Kashimura; M Fukuda; R Kishi
Journal:  Diabetes Obes Metab       Date:  2004-07       Impact factor: 6.577

9.  Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults.

Authors:  Alka M Kanaya; Tamara Harris; Bret H Goodpaster; Fran Tylavsky; Steven R Cummings
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

10.  Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.

Authors:  J H F Rudd; E A Warburton; T D Fryer; H A Jones; J C Clark; N Antoun; P Johnström; A P Davenport; P J Kirkpatrick; B N Arch; J D Pickard; P L Weissberg
Journal:  Circulation       Date:  2002-06-11       Impact factor: 29.690

View more
  7 in total

1.  Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma.

Authors:  Michael T Paris; Helena F Furberg; Stacey Petruzella; Oguz Akin; Andreas M Hötker; Marina Mourtzakis
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-01-19       Impact factor: 4.016

Review 2.  The role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions.

Authors:  Amedeo Tirandi; Federico Carbone; Fabrizio Montecucco; Luca Liberale
Journal:  Eur J Clin Invest       Date:  2021-11-08       Impact factor: 5.722

3.  The Effect of Obesity on the Availabilities of Dopamine and Serotonin Transporters.

Authors:  Su Bong Nam; Keunyoung Kim; Bum Soo Kim; Hyung-Jun Im; Seung Hun Lee; Seong-Jang Kim; In Joo Kim; Kyoungjune Pak
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

4.  Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer.

Authors:  Sunghwan Suh; Tae Sik Goh; Yun Hak Kim; Sae-Ock Oh; Kyoungjune Pak; Ju Won Seok; In Joo Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

Review 5.  Non-alcoholic fatty liver disease in lean individuals.

Authors:  Somaya Albhaisi; Abhijit Chowdhury; Arun J Sanyal
Journal:  JHEP Rep       Date:  2019-08-30

6.  HELICAL COMPUTERIZED TOMOGRAPHY CAN MEASURE SUBCUTANEOUS, VISCERAL AND TOTAL FAT AREAS?

Authors:  Guilherme Wendler; Paulo Afonso Nunes Nassif; Osvaldo Malafaia; Eduardo Wendler; Ilana Barrichello Torres Wendler; Luiza Marcelli Cirpiani
Journal:  Arq Bras Cir Dig       Date:  2022-01-05

7.  Association between visceral adipose tissue volume, measured using computed tomography, and cardio-metabolic risk factors.

Authors:  Wook Yi; Keunyoung Kim; Myungsoo Im; Soree Ryang; Eun Heui Kim; Mijin Kim; Yun Kyung Jeon; Sang Soo Kim; Bo Hyun Kim; Kyoungjune Pak; In Joo Kim; Seong-Jang Kim
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.